

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

Received: 10 August 2021

Accepted: 1 August 2022

Published online: 08 September 2022

 Check for updates

Alexandra Gyurdieva¹, Stefan Zajic¹, Ya-Fang Chang¹, E. Andres Houseman¹, Shan Zhong¹, Jaegil Kim¹, Michael Nathenson¹, Thomas Faitg¹, Mary Woessner¹, David C. Turner¹, Aisha N. Hasan¹, John Glod², Rosandra N. Kaplan², Sandra P. D'Angelo^{3,4}, Dejka M. Araujo⁵, Warren A. Chow⁶, Mihaela Druta⁷, George D. Demetri⁸, Brian A. Van Tine⁹, Stephan A. Grupp¹⁰, Gregg D. Fine¹ & Ioanna Eleftheriadou¹ ✉

Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic synovial sarcoma, with 50% overall response rate. The efficacy of lete-cel treatment in 45 synovial sarcoma patients (NCT01343043) has been previously reported, however, biomarkers predictive of response and resistance remain to be better defined. This post-hoc analysis identifies associations of response to lete-cel with lymphodepleting chemotherapy regimen (LDR), product attributes, cell expansion, cytokines, and tumor gene expression. Responders have higher IL-15 levels pre-infusion ($p = 0.011$) and receive a higher number of transduced effector memory (CD45RA⁻ CCR7⁻) CD8⁺ cells per kg ($p = 0.039$). Post-infusion, responders have increased IFN γ , IL-6, and peak cell expansion ($p < 0.01$, $p < 0.01$, and $p = 0.016$, respectively). Analysis of tumor samples post-treatment illustrates lete-cel infiltration and a decrease in expression of macrophage genes, suggesting remodeling of the tumor microenvironment. Here we report potential predictive and pharmacodynamic markers of lete-cel response that may inform LDR, cell dose, and strategies to enhance anticancer efficacy.

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment for hematologic malignancies^{1,2}, but have shown limited efficacy in solid tumors³. Clinical activity in solid tumors, including metastatic HPV-associated carcinomas, melanomas, synovial sarcomas (SS), and myxoid/round cell liposarcomas (MRCLS), has been observed with engineered T-cell receptor (TCR) T cells^{4–9}. In contrast to CAR

T cells which recognize cell surface antigens, TCR T cells are engineered with a TCR specific for peptides from intracellular cancer antigens presented by a human leukocyte antigen (HLA) molecule¹⁰. Letetresgene autoleucel (lete-cel; GSK3377794) consists of autologous CD4⁺ and CD8⁺ T-cells transduced with a high-affinity TCR recognizing the NY-ESO-1 (New York esophageal squamous cell carcinoma 1)

¹GlaxoSmithKline, Collegeville, PA, USA. ²National Cancer Institute, Bethesda, MD, USA. ³Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁴Weill Cornell Medical Center, New York, NY, USA. ⁵University of Texas/MD Anderson Cancer Center, Houston, TX, USA. ⁶City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ⁷H. Lee Moffitt Cancer Center, Tampa, FL, USA. ⁸Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA, USA. ⁹Washington University in St. Louis School of Medicine, St. Louis, MO, USA. ¹⁰Kelly Center for Cancer Immunotherapy, Division of Oncology, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA, USA. At time of study design: Shan Zhong, David C. Turner, Aisha N. Hasan, Gregg D. Fine. ✉e-mail: ioanna.x.eleftheriadou@gsk.com

antigen in complex with specific *HLA-A*02* alleles⁷. NY-ESO-1-specific TCR T cells have shown robust clinical efficacy in SS. One clinical trial of retrovirally transduced NY-ESO-1 TCR T cells with interleukin (IL)-2 treatment (NCT00670748) demonstrated objective clinical responses in 61% of patients with SS⁹, and study NCT01343043 identified anti-tumor responses in up to 50% of advanced SS patients treated with lete-cel⁷.

SS is characterized by an SS18-SSX 1, 2, or 4 fusion protein formed by chromosomal translocations at t[X; 18] [p11;q11]. This, in the proper cell context, drives malignant transformation via epigenetic disturbances of the SWI/SNF complex^{11,12}. The translocation also causes aberrant upregulation of NY-ESO-1, which is expressed in ~80% of SS tumors^{13,14}. SS tumors have been characterized as immune deserts with exceptionally low immune cell infiltration compared with other soft tissue sarcoma (STS) subtypes^{15–17}. Macrophages are the predominant infiltrates and are associated with poor prognosis in SS^{16,18}. Poor immune cell infiltration, coupled with low tumor HLA expression and mutational burden^{15,19,20} likely render SS less susceptible to non-cellular immunotherapies, with rare responses observed with immune checkpoint inhibitors^{21,22}. The challenges associated with immunotherapies in SS underscore the significance of the clinical responses reported with TCR T-cell therapies.

To further increase treatment efficacy, it is necessary to identify cell product characteristics and biomarkers predictive of response. Peak cell expansion and cytokine levels on day of and post-infusion have been linked to response or remission to CAR T cells in hematological malignancies^{23,24}. However, few biomarker correlates have been identified for solid tumors with engineered cell therapies. We report findings from a post-hoc analysis of study NCT01343043, identifying specific attributes of lymphodepleting chemotherapy regimens (LDRs), cell dose, and cell product which impact in vivo cell expansion and correlate with clinical response. We also report preliminary trends of lete-cel treatment-induced decrease of macrophage gene expression within the tumor microenvironment (TME). The findings from this comprehensive dataset contribute towards the progressive understanding of mechanisms of response and resistance to TCR T-cell therapy in SS, a model for solid tumors, and provide considerations for further immunotherapy developments.

Results

Standard LDR creates favorable conditions for infused T cells and highlights benefits of higher cell dose

Patients with advanced or metastatic SS were enrolled to four cohorts designed to evaluate the impact of varying NY-ESO-1 expression levels and LDR on response (Table 1). Baseline patient characteristics were similar across cohorts (Table S1). The primary endpoint was overall response rate as assessed by investigators and was 50% in Cohort 1, as previously reported by D'Angelo, et al.⁷, 31% in Cohort 2, 20% in Cohort 3, and 27% in Cohort 4 (Table 1). Review by an independent committee was performed as a sensitivity analysis and the results agreed with a high concordance of 89%. Response rates were unchanged for Cohorts 1 and 3 and increased to 46% and 47% in cohorts 2 and 4 respectively (Table 1). The secondary efficacy endpoints included best overall response, duration of response (DoR), progression-free survival (PFS) and overall survival (OS). Best overall response and DoR were previously reported by D'Angelo, et al. for Cohort 1 and Ramachandran, et al. for all cohorts^{7,8}. Here we report median DoR ranging from 8.6 to 32.1 weeks, median PFS ranging from 8.6 to 22.4 weeks and median OS ranging from 9.9 to 26.2 months across cohorts (Table 1). The safety profile of Cohort 1 was previously reported by D'Angelo, et al.⁷. Here we report on safety events across all cohorts. Observed safety events were expected and consistent with lymphodepletion and T-cell activation, including cytopenias and cytokine release syndrome (Table S2, Table S3). Eleven patients were eligible for a second infusion of lete-cel. Two patients responded post second infusion, while the remaining

patients had stable disease with evidence of changes in tumor size (Table S4). This exploratory, post-hoc analysis focuses on correlates post first infusion and considers responders as patients whose tumors had a partial or complete response as assessed by investigators. Biomarker associations presented here that are significant with investigator-assessed response remained significant when analyzed with response as assessed by independent review committee.

To understand differences across cohorts, we evaluated the impact of NY-ESO-1 expression and LDR on response. Patients in Cohort 2 were eligible for enrollment based on a lower percentage and lower intensity of NY-ESO-1 tumor staining (Table 1). We found most patients enrolled in Cohort 2 had $\geq 30\%$ of tumor cells positive for NY-ESO-1 (Fig. S2a) and the median NY-ESO-1 expression across all cohorts was 80%. This high expression of NY-ESO-1 in SS is consistent with published reports¹³ and showed no significant impact on response (Fig. S2a).

The proposed role of LDRs is to reduce elements of the endogenous immune system that compete with infused T cells for supportive cytokines^{25,26}. Depletion of endogenous lymphocytes and monocytes prior to infusion varied significantly by cohort, with more complete depletion observed with standard LDR (Fig. 1a, b). IL-15 and IL-7 are cytokines which support T-cell proliferation and survival²⁶ and studies have shown that these cytokines are increased post LDR, especially by fludarabine^{8,24,27,28}. Consistent with this, we observed that patients that received LDRs containing fludarabine had higher IL-15 levels prior to T-cell infusion (Fig. 1c). The role of fludarabine was further demonstrated by data from two patients who received cyclophosphamide-only LDR for the first infusion and fludarabine-containing LDR for the second infusion. These patients had 2- and 7-fold increase in IL-15 respectively (Fig. S2b). Furthermore, across the cohorts responding patients had higher levels of IL-15 prior to T-cell infusion (Fig. 1d). There was no association of IL-7 pre-infusion with response (Fig. S2c). Use of standard LDR appeared to create favorable conditions for T-cell proliferation.

With a proliferation-permissive environment established by a standard LDR, we evaluated the impact of transduced cell dose (hereafter cell dose) on tumor reduction in patients from Cohorts 1 and 2. As shown in Fig. 1e, there was an inverse linear relationship of cell dose normalized by body weight with tumor volume reduction, which trended towards significance ($p = 0.058$). There was a trend of responders receiving a higher cell dose per kg (cell dose/kg) compared to non-responders (median $0.059 \times 10^9/\text{kg}$ and $0.027 \times 10^9/\text{kg}$ respectively; $p = 0.088$) (Fig. S2d). This analysis controlled for any effects of LDR on tumor size, since patients included received the same LDR. These data demonstrate that a higher cell dose per kg in combination with standard LDR may offer opportunities to maximize antitumor efficacy.

Standard LDR and higher weight-normalized cell dose are associated with higher peak cell expansion which is a marker of response

Following evaluation of pre-infusion correlates, we analyzed the expansion of lete-cel post-infusion and found responders across cohorts had higher peak cell expansion (Cmax) ($p = 0.016$, Fig. 2a), consistent with what was previously reported for Cohort 1⁷. Higher Cmax was associated with standard LDR ($p = 0.00163$) and higher weight-normalized cell dose ($p = 0.00421$) (Fig. 2b, c). The association of absolute dose with Cmax was weaker though still present (Fig. S3a). There was a trend towards higher persistence levels at Week 4 in responders ($p = 0.0518$) (Fig. 2d). Area under the cell expansion curve from day 0 to day 28 was closely correlated with Cmax and had similar association with response (Fig. S3b, c). There were no associations between baseline tumor burden and NY-ESO-1 expression with Cmax or response (Fig. S3d–f). In addition to response, higher Cmax was associated with longer progression-free survival (PFS) ($p = 0.028$)

Table 1 | Summary of efficacy results across study cohorts

Parameter	Cohort 1 (n = 12)	Cohort 2 (n = 13)	Cohort 3 (n = 5)	Cohort 4 (n = 15)
NY-ESO-1 Expression (IHC Score)	HIGH 2+ or 3+ in ≥50% of tumor cells	LOW ≥1+ in ≥1% cells but not exceeding 2+ or 3+ in ≥50% cells		HIGH 2+ or 3+ in ≥50% of tumor cells
Lymphodepletion regimen		STANDARD fludarabine (30 mg/m ² × 4D) and cyclophosphamide (1800mg/m ² × 2D)	CYCLOPHOSPHAMIDE ONLY (1800mg/m ² × 2D)	REDUCED fludarabine (30 mg/m ² × 3D) and cyclophosphamide (600 mg/m ² × 3D)
Median transduced cell dose (*10 ⁹) (Range*10 ⁹) ^a	3.60 (0.45–14.36)	2.42 (1.60–5.01)	3.02 (1.53–5.00)	2.40 (1.00–4.95)
Investigator Assessed ^b (Primary Endpoint)				
Overall response rate ^b n (%) (95% CI)	6 (50%) (0.21–0.79)	4 (31%) (0.09–0.61)	1 (20%) (0.01–0.72)	4 (27%) (0.08–0.55)
Best Overall Response ^c n(%)				
Complete Response	1 (8%)	0	0	0
Partial Response	5 (42%)	4 (31%)	1 (20%)	4 (27%)
Stable Disease	5 (42%)	7 (54%)	3 (60%)	10 (67%)
Progressive Disease	1 (8%)	1 (8%)	0	1 (7%)
Not evaluable	0	1 (8%)	1 (20%)	0
Median DoR (range), weeks	31.0 (13–72)	8.6 (8–13)	32.1 (32–32)	16.4 (14–94)
Median PFS ^f (95% CI), weeks	15.4 (7.7–38.0)	13.1 (7.9–13.9)	8.6 (0.7–36.1)	22.4 (11.3–26.6)
Median OS (95% CI), months ^d	24.3 (8.5–48.8)	9.9 (3.9–19.6)	19.9 (8.8–NA)	26.2 (9.2–40.6)
Independent Review Committee ^{e,g} Overall response rate ^b n (%) (95% CI)	6 (50%) (0.21–0.79)	6 (46%) (0.19–0.75)	1 (20%) (0.01–0.72)	7 (47%) (0.21–0.73)

CI confidence interval, DoR duration of response, NA not available, OS overall survival, PFS progression-free survival, IHC immunohistochemistry, NY-ESO-1, New York esophageal squamous cell carcinoma 1.

^aData from modified intent-to-treat population: all patients that received lete-cel infusion.

^bProportion of patients with a confirmed CR or PR relative to total number of patients with 95% Clopper-Pearson confidence intervals.

^cRecorded from the time of first T-cell infusion until disease progression.

^dData from Long-Term Follow-up Study, cut-off April 23, 2021.

^eReview by an independent committee was performed as a sensitivity analysis for the primary endpoint which was based on investigator assessment.

^fPFS was defined as the time from T-cell infusion to the earliest documentation of disease progression or death from any cause or surgical resection or start of prohibited medication.

(Fig. 2e). Cell dose was not associated with PFS (Fig. S3g). These data further support the use of a standard LDR and the benefits of providing a higher cell dose/kg, when possible, to enable T cell expansion post infusion in synovial sarcoma.

Responders received lete-cel product enriched with activated, effector memory CD8 cells and containing comparable total CD8 to CD4 cell ratio


Lete-cel contains a mixture of transduced and non-transduced T cells. In this study, the median transduction efficiency was 35% (range 14–65%). To characterize the transduced cells, we used an NY-ESO-1 major histocompatibility complex (MHC) class I pentamer reagent. This pentamer is primarily used to stain CD8 cells due to co-receptor stabilization²⁹, therefore our analysis focused on CD8 + Pentamer+ cells.

On average, responders had 28% CD8 + Pentamer+ cells with an effector memory (EM) phenotype (CD45RA- CCR7-) (Fig. S4a, b). Since cell dose/kg has been shown to have an impact on response (Fig. 1e), we consider it important to analyze the absolute number of cells per phenotype infused. Notably, responders received a higher number of CD8 + Pentamer+ EM cells/kg, with a median of 12 million/kg compared to 4 million/kg for non-responders (Fig. 3a). No significant difference in other memory phenotype cells, such as T stem cell memory (TSCM) or central memory (CM), received by responders and non-responders, was observed in this study. A similar trend was observed when further analyzed as a logistic regression (Fig. S4c). Additionally,

the number of CD8 + EM and CM cells infused were associated with Cmax ($p = 0.0094$ and $p = 0.0017$, respectively) (Fig. 3b). As T cells differentiate from naïve to terminal effector cells, their specialized function drives production of certain cytokines. We analyzed the relationship between infused memory phenotypes and levels of interferon (IFN) γ , a key cytokine for promoting host-immune recruitment to tumors³⁰. Figure 3c shows an association between the number of CD8 + EM cells infused and peak IFN γ post-infusion ($p = 0.019$). This is an interesting finding, suggesting a link between the product phenotype and the functionality of these cells post-infusion.

To better understand factors that affect product attributes, the impact of the starting apheresis material was evaluated. There was a significant association between percent CD8 + EM in apheresis material and product ($p = 0.01$), with the majority of responders starting with >30% CD8 + EM (Fig. 3d, Fig. S4d). This highlights the possibility of the apheresis material to influence product characteristics and potentially identify patients who are more likely to respond. Further analysis is needed to identify patient characteristics that may influence the starting proportion of EM cells.

Together these findings demonstrate that CD8 + EM cells are important for lete-cel response in SS. When the impact of CD8 + EM cells on PFS was analyzed, there was only a trend toward increased PFS with higher percentage and number of infused cells/kg ($p = 0.055$ and $p = 0.072$, respectively) (Fig. 4a). This points to additional factors or cell populations which may be needed to achieve prolonged response.



At Week 4, responders had higher levels of CD8 + Pentamer+ cells (Fig. 4b), consistent with DNA-based persistence results (Fig. 2d, S5a). Of these remaining cells, ~50% were characterized by a T naïve/stem-like phenotype (CD45RA + CCR7+) (Fig. 4c), suggesting this cell type may be beneficial for long-term persistence.

Further analysis of the product revealed responders received cells characterized by an activated phenotype and comparable ratio of total CD8+ to CD4+ cells. Cells expressed CD40 ligand (CD40L) which

was associated with an EM phenotype (Fig. S5b, c). There was no association of PD-1, LAG-3, CTLA-4, or TIM-3 expression levels in the apheresis and product with response (Fig. S5d, e); differential expression of TIM-3 between apheresis and product suggests upregulation as a result of activation during the manufacturing process. The comparable ratio of total CD8+ to CD4+ cells in responders suggests CD4+ cells may be important to support CD8 function (Fig. S5f).

Fig. 1 | Standard LDR of fludarabine and cyclophosphamide forms supportive environment for T cells and highlights impact of cell dose. a, b Endogenous lymphocyte (a) and monocyte (b) cell counts across cohorts on day of infusion ($n = 43$ biologically independent samples). All responders except two in Cohorts 3 and 4 had <10 lymphocytes/ μL prior to T-cell infusion. c, d, IL-15 levels prior to T-cell infusion across cohorts (c) and association with response (d) ($n = 34$ biologically independent samples). Values are log-transformed for consistency with other cytokine analyses. ANOVA and t -test were performed in c and d to be consistent with remaining cytokine analyses; Kruskal–Wallis p -value = 0.005 for (c) and Wilcoxon p -value = 0.050 for d. e Impact of transduced cell dose/kg on reduction in tumor size ($n = 22$ biologically independent samples) for patients in cohorts 1 and 2.

Collectively, these data illustrate that a TCR T-cell product enriched with activated, EM CD8 cells is associated with response.

Proinflammatory cytokines identified as pharmacodynamic markers associated with response

Post lete-cel infusion, several proinflammatory cytokines were significantly increased in responders as compared with non-responders at Day 3 and 4 (Fig. 5a, b). IFN γ , IL-6, and soluble IL-2 receptor alpha (IL-2R α) were the most robust pharmacodynamic (PD) markers, while granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-17A were often present at levels below limit of quantification. Expression of these cytokines demonstrates that T cells become activated within a few days post-infusion and this occurs earlier in responders. The increased IFN γ in responders is intriguing as it highlights the impact of EM cells in the product which are associated with IFN γ production, and subsequently with response (Fig. 3a, c). The peak expression of soluble IL-2R α showed the strongest correlation to C $_{\text{max}}$, indicating a PK/PD relationship (Fig. 5c). Strong and moderate associations were also observed with GM-CSF and IL-15, respectively (Fig. S6). These robust cytokine data illustrate early activation of T cells in responders. It is encouraging to observe such large differences systemically in a solid tumor setting and suggests changes of the cytokine milieu within the TME.

Lete-cel promotes remodeling of TME by decreasing macrophage levels

While limited tumor biopsies were available in this study ($n = 15$), gene expression analysis revealed interesting trends. Consistent with previous reports^{15,16,18,31}, gene expression and immunohistochemistry (IHC) data indicated that SS tumors were primarily infiltrated by CD163 and CD68 macrophages (Fig. S7a, b). Macrophages are associated with poorer prognosis in STS^{18,32}. To understand the impact of lete-cel on the TME, we analyzed 10 pre-infusion biopsies and 5 biopsies at progression. Notably, post lete-cel infusion, there was a significant decrease in mRNA expression of macrophage markers *CD163*, *CD68*, and *CD84* (Fig. 6a). The decrease in *CD163* mRNA was confirmed by IHC in all samples (Fig. S7c) and a set of paired samples where a baseline biopsy from the lung had ~7% of the tumor area positive for CD163 compared to ~1% in a biopsy from the same lesion at progression (Day 125) (Fig. 6b). This patient was treated with 1.8 billion cells (0.033 $\times 10^9$ /kg) and had a partial response with a 55% reduction in tumor size. The growing lesion had continued expression of NY-ESO-1 (100% positive), and the patient received a second infusion ~9 months after the first. Following bridging therapy with trabectedin, the patient received the same LDR and 2 billion cells (0.042 $\times 10^9$ /kg) from a new product manufacture and had a complete response. Together, these data provide early evidence that lete-cel treatment can not only kill antigen positive tumor cells but also has the potential to remodel the TME, particularly the macrophage component.

This study highlights the negative impact of myeloid cells more broadly on lete-cel treatment. Genes involved in IFN downstream signaling were elevated in non-responders prior to infusion (Fig. 6c, d, Table S5, S6). This gene set is primarily induced by type I interferons,

such as IFN α and IFN β , with limited involvement of IFN γ . Type I interferons are known to play an important role in antiviral response as well as myeloid differentiation³³. They can have both pro- and anti-tumor effects depending on the TME, cell types, and cytokines^{34–36}. It is unclear what triggered the induction of these genes in this analysis as *IFNA* and *IFNB* RNA was undetectable in tumor cells. However, Fig. 6e shows that the gene set expression was associated with *CD163* and *CD68* macrophage expression. These data suggest a negative association of myeloid cells with lete-cel response and support further investigation of combinations with therapies that target the myeloid compartment.

To evaluate mechanisms of resistance, we analyzed biopsies obtained at progression (range, 95–276 days post-infusion) for *CTAG1B* (NY-ESO-1) and *HLA-A* gene expression. *CTAG1B* RNA expression remained high and was consistent with protein expression (Fig. 7a, S8a). There was a decrease in *HLA-A* and genes involved in antigen presentation at progression (Fig. 7a, b). This could be one means of antigen escape, as HLA-A is necessary for presentation of the NY-ESO-1 peptide to T cells. Availability of paired biopsies limited this analysis, so data are presented for all evaluable samples, but similar trends were observed with three paired biopsies. Further analyses are necessary to understand if this decrease is due to transcriptional downregulation, which could be upregulated in response to IFN γ ³⁵, or mutations in antigen-presenting genes.

Analysis of genes linked to cancer progression, such as *TGFB* and *WNT* was also performed. As expected, we found high expression of these genes in SS^{11,37}. Since expression of these genes was uniformly upregulated, no association with response or PFS was observed (Fig. S8b, c). With limited immune cell infiltration, expression of exhaustion markers was low at all timepoints and had no association with response or PFS (Fig. S8d, e). However, these are bulk RNA analyses which are limited in their ability to characterize rare cell types; single-cell profiling should be conducted in the future to analyze T-cell specific gene signatures.


The need for scRNAseq analysis is highlighted in an interesting case of a responder with evidence of lete-cel tumor infiltration in a biopsy taken 919 days post-infusion and persistence of cells in the blood for >1500 days (Fig. 7c). Further IHC analysis of this sample revealed continued expression of NY-ESO-1 (90% positive) as well as expression of PDL1 and LAG-3 in a similar region of the tissue as lete-cel (Fig. 7d). Future scRNAseq analysis will enable specific characterization of infiltrating T-cells to further our understanding of mechanisms of resistance.

Together these data demonstrate that lete-cel traffic into the tumor and promote tumor remodeling with associated decreases in macrophage levels, offering key insights into considerations for subsequent treatments and combinations of therapies aiming to enhance antitumor effects.

Together these data demonstrate that lete-cel traffic into the tumor and promote tumor remodeling with associated decreases in macrophage levels, offering key insights into considerations for subsequent treatments and combinations of therapies aiming to enhance antitumor effects.

Discussion

TCR T-cell therapies have shown encouraging clinical results in several solid tumor types^{4–9}, including up to 50% overall response rates with lete-cel in SS⁷. However, few biomarker correlates with cell therapy



response in solid tumors have been identified. This comprehensive analysis of 45 SS patients treated with lete-cel identified significant associations between LDR, cell dose, and product attributes with response for the first time. These data demonstrate that LDRs containing fludarabine augment IL-15 levels prior to infusion, which is associated with response. Furthermore, standard LDR together with

cell dose/kg increases cell expansion and probability of response. Analysis of the product revealed activated, EM cells were associated with response. Finally, tumor analyses post-infusion illustrated lete-cel infiltration into an immune desert tumor and remodeling of the TME by decreasing macrophage levels. Though data are limited by number of patients and available samples, these findings are intriguing and

Fig. 2 | Lete-cel expansion post-infusion associated with response, cell dose/kg, and LDR. **a** Association of peak cell expansion (Cmax) with response ($n = 43$ biologically independent samples). **b, c**, Relationship of Cmax with weight-normalized cell dose with line of best fit in blue (**b**) and LDR (**c**) ($n = 43$ biologically independent samples). **d** Persistence of lete-cel at Week 4 post-infusion in all 4 cohorts, stratified by response ($n = 35$ biologically independent samples). **e** Relationship between Cmax and PFS ($n = 43$ biologically independent samples). PFS was defined as the time from T-cell infusion to the earliest documentation of disease progression or death from any cause or surgical resection or start of prohibited medication. Box

plots depict median as horizontal line within box, with box bounds as the first and third quartiles. Dots represent individual data points. Lower whisker is the minimum value of the data within 1.5 times the interquartile range below the 25th percentile. Upper whisker is the maximum value of the data within 1.5 times the interquartile range above the 75th percentile. Two-sided p -values were calculated via Wilcoxon test (**a, c, d**) or linear (**b**) regression, and Cox proportional hazards model (**e**). CR complete response, Cy cyclophosphamide, LDR lymphodepleting chemotherapy regimen, PD progressive disease, PFS progression-free survival PR partial response, SD stable disease.

suggest directions for cell dose and LDR optimization, balanced composition of product phenotypes, efficacy enhancement technologies, and combinations of therapies to positively impact clinical response. Further work is required and ongoing to validate these observations in a larger set of patients and paired biopsies.

Many of our findings are consistent with observations of CAR T-cell therapy in hematologic malignancies, suggesting similar mechanisms of action. With both cell therapy modalities, peak cell expansion is associated with response^{38–40}. We also report a relationship between cell dose and expansion that has been reported for TCR T-cell therapies but is not well defined for CAR T cells^{6,27}. Our observations align with reports that LDRs containing a combination of cyclophosphamide and fludarabine led to increased CAR T-cell expansion as well as greater increases in IL-15^{8,24}. The association of IL-15 with response supports future exploration of lete-cel in combination with IL-15 agonists. Post-infusion, significant increases in the levels of IFN γ , IL-6, and GM-CSF were observed in responders, suggesting T-cell activation, in line with previous reports²⁸.

The association of infused EM CD8 T cells with response is a unique finding for TCR T-cell therapy. The impact of EM cells has been highlighted in the context of response to checkpoint inhibitors^{41,42}, but only one study has performed a similar characterization of TCR T-cell product. Nagarsheth, et al. found that HPV-16 E7 TCR T-cell product consisted primarily of EM and TEMRA cells, though there was no association with response and the impact of the number of EM cells infused was not evaluated⁶. Several studies have characterized the memory composition of CAR T-cell products and have underscored the role of stem-like and CM cells and/or genes for durable responses in hematologic malignancies^{38,43–45}. These observations suggest different cell populations may play unique roles for immediate versus durable response and CAR T cells versus TCR T cells. Unlike CAR T cells that recognize cell surface antigens, TCR T cells recognize an antigen presented by an HLA molecule, and therefore depend on HLA for target recognition and activation. Interestingly, although HLA expression on the tumor is low in SS^{15,19}, we observed responses with lete-cel. Based on our findings, we hypothesize that EM cells are necessary to upregulate HLA expression through IFN γ . EM cells are characterized by higher IFN γ production than CM or stem-like cells^{46,47} and this is further supported in this study by the correlation of CD8 EM cells to peak IFN γ post-infusion (Fig. 3d). Several studies have demonstrated a key role of IFN γ in promoting host-immune recruitment to tumors³⁰. Zhang, et al. showed that systemic IFN γ treatment of SS and MRCLS tumors led to increased expression of HLA-ABC which subsequently increased T-cell infiltration³⁵. In this study, the ability to confirm HLA upregulation was limited by availability of tumor biopsies collected soon after T-cell infusion. Future studies to characterize the TME within a few weeks post-infusion and gene profiling to better define cell populations in the product will be beneficial. Techniques that link gene expression to traditional cell markers will aid in identifying specific populations of interest; current studies use a mixture, which makes comparison across studies difficult. The enrichment of CD8 EM cells in the apheresis of responders and the associations of infused CD8 EM cells with response, Cmax, and peak IFN γ consistently highlight the importance of this cell type for lete-cel treatment of SS. Further studies are necessary to understand the balance of EM cells,

associated with response, and stem-like cells, which may be beneficial for cell persistence.

Treatment of solid tumors with cell therapies poses several challenges such as T-cell trafficking into the tumor and an immune-suppressive TME^{48–50}. SS tumors in particular are characterized by a core oncogenic program which is associated with immune cell evasion⁵¹. Though tumor samples were limited, data illustrated the ability of lete-cel to infiltrate the tumor and promote changes in the immune microenvironment. This is in line with a recent report that CAR T-cells reshape the TME and recruit and activate host-immune cells to the tumor through IFN γ and IL-12³⁰. Our TME analyses revealed that elevated IFN response genes, involved in myeloid differentiation and recruitment, were associated with non-responders and that levels of macrophage genes decreased post lete-cel treatment. These findings are consistent with reports of IFN pathway involvement in resistance to CAR T cells⁵² and association of macrophages with poor prognosis in STS^{18,32}. Such tumor remodeling could have an important impact on patient response with subsequent treatments.

In terms of mechanisms of resistance, we evaluated antigen loss and T-cell exhaustion^{33,54}. Since the SS patients in this study had high expression of NY-ESO-1 at screening, our data showed no association with response. This may differ in tumor types with more heterogeneous NY-ESO-1 expression, such as non-small cell lung cancer, gastric, and others. Gene expression analysis revealed no change in NY-ESO-1 expression post-treatment, consistent with previous reports⁸, but a decrease in HLA-A expression and antigen-presenting genes, which may be a mechanism of antigen escape. Nagarsheth et al. reported similar findings of *HLA* and *B2M* mutations in tumor biopsies from three patients who showed no response or relapse to treatment with HPV-16 E7 TCR T cells⁶. Loss of heterozygosity of HLA genes has also been reported as a mechanism of immune evasion in treatment with tumor-infiltrating T-cell therapy⁵⁵. Further analysis is needed to determine if the observed downregulation of HLA in this study is due to transcriptional differences, mutations, or copy number variations. If these are transcriptional differences, strategies to maintain upregulation of HLA over time should be considered. For evaluation of exhaustion markers, this study highlighted limitations of bulk gene expression analysis to characterize tumors with few immune infiltrates and pointed to the benefits of single-cell profiling techniques. Collectively, these data provide unique insights into combinations to further enhance responses: for example, therapies that can decrease the myeloid and macrophage components or upregulate antigen presentation.

This study highlighted the benefits of standard LDR and higher cell dose for robust T-cell expansion, identified product attributes associated with response, and showed a trend in tumor remodeling post T-cell infiltration. Future investigations will include how lete-cel treatment and tumor remodeling may affect the endogenous T-cell repertoire. Our analysis also provided valuable insight into the development of next-generation engineered T-cell technologies, for example data supporting the benefit of CD4 T cells in the product and the high expression of TGF- β in SS tumors. Technologies focused on increasing the persistence of CD4 T cells through co-expression of CD8 α to stabilize the HLA interaction, as well as reducing the inhibitory effect of TGF- β on T cells through a dominant negative receptor,




Fig. 3 | T-cell product enriched with activated, effector memory CD8 cells is associated with response. **a** Number of CD8 + Pentamer+ cells/kg infused per memory phenotype in non-responders vs responders ($n = 36$ biologically independent samples). **b, c** Association of number of infused cells/kg per memory phenotype with peak cell expansion (**b**) and peak IFN γ post-infusion (**c**) ($n = 34$ and 31 biologically independent samples for parts **b** and **c** respectively). Associations with EM cells are statistically significant with outlier at lowest infused cell counts removed—EM with Cmax ($R = 0.42$, $p = 0.016$) and EM with IFN γ ($R = 0.41$, $p = 0.027$). **d** Association of EM phenotype between apheresis and product ($n = 34$ biologically independent samples). Box plots depict median as horizontal line within box, with box bounds as the first and third quartiles. Dots represent

individual data points. Lower whisker is the minimum value of the data within 1.5 times the interquartile range below the 25th percentile. Upper whisker is the maximum value of the data within 1.5 times the interquartile range above the 75th percentile. Nominal two-sided p -values based on the Wilcoxon rank sum test or log-rank test for PFS are presented and correlations are based on Spearman method. Line of best fit shown in blue for significant associations and gray area represents 95% confidence interval around the regression line. CM central memory (CD45RA-CCR7+), CR complete response, EM effector memory (CD45RA-CCR7-), Naïve (CD45RA + CCR7+), PFS progression-free survival, PD progressive disease, PR partial response, SD stable disease, TEMRA T effector memory RA (CD45RA + CCR7-), TSCM T stem cell memory (CD45RA + CCR7 + CD45RO-CD95 + CD127+).




Fig. 4 | Characterization of transduced T cells post infusion. **a** Association of % and number of CD8+ Pentamer+EM cells/kg with PFS. PFS was defined as the time from T-cell infusion to the earliest documentation of disease progression or death from any cause or surgical resection or start of prohibited medication ($n = 36$ biologically independent samples). Blue and red shaded areas represent 95% confidence interval for the survival curve. **b** Levels of CD8 + Pentamer+ cells at Week 4. **c** Levels and composition of memory phenotypes of CD8 + Pentamer+ cells post-infusion. Product analyses consist of 36 patients. Number of patients for post-infusion analyses are listed on figures. Box plots depict median as horizontal line within box, with box bounds as the first and third quartiles. Dots represent

individual data points. Lower whisker is the minimum value of the data within 1.5 times the interquartile range below the 25th percentile. Upper whisker is the maximum value of the data within 1.5 times the interquartile range above the 75th percentile. Nominal two-sided p -values based on the Wilcoxon rank sum test or log-rank test for PFS are presented and correlations are based on Spearman method. CM central memory (CD45RA-CCR7+), CR complete response, EM effector memory (CD45RA-CCR7-), Naïve (CD45RA + CCR7+), PFS progression-free survival, PD progressive disease, PR partial response, SD stable disease, TEMRA T effector memory RA (CD45RA + CCR7-), TSCM T stem cell memory (CD45RA + CCR7 + CD45RO-CD95 + CD127+).

are already being evaluated and it will be interesting to monitor impact on efficacy and biomarkers in this study (NCT04526509). Future work will evaluate the strength of these biomarker correlations in disease indications beyond SS, such as MRCLS and non-small-cell lung carcinoma. The findings of our study contribute to better understanding of mechanisms underlying response and resistance to engineered TCR T-cell therapies in SS, a model for solid tumors.


Methods

Study design

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines following approval by the following ethics committees and institutional review boards at each study site: National Institutes of Health Intramural Institutional Review Board, Memorial Sloan Kettering Cancer Center Institutional Review Board/Privacy Board, The University of Texas M.D. Anderson Cancer Center Institutional Review Board, City Of Hope Institutional Review Board, University of South Florida, Research Integrity & Compliance Office Institutional Review Board-Human Research Protection Program, Dana Farber Cancer Center Institutional Review Board, Washington University School of Medicine in Saint Louis, Department Human

Research Protection Office, and Office of Human Subject Protection at The Children's Hospital of Philadelphia. All patients provided written informed consent prior to the performance of any study-specific procedures. The investigator agreed to provide the subject sufficient time to review the document, to inquire about details of the trial, and to decide whether or not to participate in the study. The informed consent was signed and dated by the study subject and by the person who conducted the informed consent discussion. The informed consent for pediatric subjects was signed and dated by the parent or legal guardian of the study subject and by the person who conducted the informed consent discussion. No participant compensation was given except for travel/lodging expenses reimbursement.

This was a multicenter, open-label, pilot study to determine the efficacy and safety of lete-cel in patients with unresectable, metastatic, or recurrent SS. Study stages included screening, leukapheresis/manufacture, lymphodepletion, and treatment phases, followed by long-term follow-up performed under a separate protocol (Fig. S1). Patient were screened for HLA and NY-ESO-1 and considered enrolled at the time of leukapheresis. The total population enrolled (underwent apheresis) and thus considered for the intent to treatment analysis (ITT) was 50 patients (cohort 1: 15, cohort 2: 14, cohort 3: 5, cohort



4:16). A total of five patients dropped out between leukapheresis and T cell infusion. Three patients dropped out due to death (one each from cohort 1, 2, 4), one patient withdrew consent (cohort 1), and one patient withdrew due to disease progression prior to treatment (cohort 1). The modified ITT (mITT) population was 45 patients (cohort 1: 12, cohort 2: 13, cohort 3: 5, cohort 4 :15). The mITT population

included 47% (21/45) females and 53% (24/45) males with a median age of 32 years (range of 11–73 years) (Table S1).

Study participants

Inclusion criteria. Patients had to be ≥ 4 years of age, >18 kg, have Eastern Cooperative Oncology Group (ECOG) performance status of

Fig. 5 | Increase in proinflammatory cytokines in responders post lete-cel infusion and correlation to peak cell expansion. **a** Heatmap of Responder vs Nonresponder ratios in cytokine levels over time obtained from linear mixed effects (LME) model. T-cell infusion (TCI) occurred on Day 0. Nominal *p*-values from linear effects models were calculated via Wald test and *t*-distribution and are shown as one dot for $0.01 < p \leq 0.05$ and two dots for $p \leq 0.01$. **b** Time courses of IFN γ , IL-6, IL-17A, and GM-CSF, cytokines differentially upregulated by responders. Geometric means and 95% confidence intervals from LME model (accounting for left-censoring where appropriate) are plotted. Dashed, horizontal lines represented

lower limit of quantification. **c** Time course of soluble IL-2R α levels showing increase in responders and correlation to peak cell expansion. Line of best fit shown in black and gray area represents 95% confidence bands, both from standard least-squares regression. Sample size varied across timepoints and cytokines, with an overall median of 32 patients (range, 15–38 depending on cytokine/timepoint). For **c**, Spearman correlation and corresponding two-sided *p*-value are presented. DY day, GM geometric mean, GM-CSF granulocyte-macrophage colony-stimulating factor, IFN interferon, IL interleukin, WK week.

0–1 (or Lansky >60 for children aged ≤ 10 years), life expectancy >3 months, and adequate organ function. Additional eligibility requirements were: measurable, pathologically, or cytologically-diagnosed unresectable or metastatic or progressive/persistent or recurrent SS previously treated with and intolerant/non-responsive to a standard chemotherapy regimen containing ifosfamide and/or doxorubicin; NY-ESO-1 positivity, with criteria as detailed for individual cohorts in Table 1; and *HLA-A*02:01*-, *HLA-A*02:05*-, and/or *HLA-A*02:06*-positivity by high-resolution testing.

Exclusion criteria. Patients were excluded if they had alanine aminotransferase levels >2.5 times the upper limit of the normal range (ULN) without documented liver metastases/tumor infiltration; total bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN was acceptable if bilirubin was fractionated and direct bilirubin was <35%); current active liver or biliary disease; clinically significant systemic illness; untreated CNS metastasis; previous treatment with genetically engineered NY-ESO-1-specific T cells; or a history of active, chronic, or recurrent severe autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments.

Study treatment and procedures

Lete-cel manufacture. Autologous T cells were manufactured from patient derived apheresis at either Cell and Vaccine Production Facility at the University of Pennsylvania or at Progenitor Cell Therapy. CD25-depleted CD4+ and CD8+ T cells were activated and expanded using α CD3/ α CD28 antibody-conjugated beads (Life Technologies) and then used to develop the engineered T cells. T cells were transduced with a self-inactivating lentivirus vector, derived from HIV-1 containing a woodchuck hepatitis virus posttranscriptional regulatory element, at a multiplicity of infection of 1 transducing unit per cell. T cell manufacturing time ranged from 28 to 35 days, including release testing. Transduction potency was measured on primary T cells.

Study procedures. Patients underwent screening assessments, including collection of blood for HLA typing and IHC evaluation of tumor for NY-ESO-1 expression, followed by biological sample collection for laboratory assessments, and collection of disease and medical history (Fig. S1). Eligible patients enrolled to the study underwent apheresis. Patients received infectious prophylaxis for *Pneumocystis carinii*, herpes zoster, and herpes simplex the day prior to commencing lymphodepletion, or as clinically indicated. Prior to lete-cel infusion, patients underwent lymphodepletion dosing as described in Table 1.

On Day 0, patients received thawed lete-cel by intravenous infusion. Patients ≥ 40 kg received a target dose of 5×10^9 transduced cells, with a minimum 1×10^9 transduced cells and a maximum of 6×10^9 transduced cells. Patients underwent radiologic disease assessments at weeks 4, 8, 12 and every 3 months thereafter, and underwent safety assessments throughout the trial at scheduled timepoints. Patients who progressed are followed for long-term toxicity until death or for up to 15 years post T cell infusion.

Patients could receive a maximum of 2 infusions with lete-cel provided eligibility criteria were met. Patients in any cohort who had a

confirmed response or had stable disease for >3 months but then progressed were eligible for a second infusion using the same lymphodepleting regimen as for the first infusion. Patients in Cohorts 3 and 4 who had progressive disease or stable disease as best response for ≤ 3 months could receive a second infusion using the high dose of fludarabine and cyclophosphamide lymphodepletion regimen. The second infusion could be given no sooner than 60 days from the first infusion and no later than 2 years after the first infusion.

Study endpoints


Efficacy. The primary efficacy outcome was investigator-assessed objective response rate (ORR; complete response or partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. This was previously reported for Cohort 1 only by D'Angelo, et al.⁷ Secondary efficacy outcomes included duration of response (DoR), progression-free survival (PFS), best overall response, and overall survival (OS). Best overall response and DoR were previously reported by D'Angelo, et al. for Cohort 1 and Ramachandran, et al. for all cohorts^{7,8}. Here we report PFS and OS across all cohorts, as well as overall response rate as assessed by independent review committee.

Safety. Secondary safety endpoints included adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESI); all were evaluated using Common Terminology Criteria for Adverse Events v4.0 (CTCAE v4.0). The safety profile of Cohort 1 was previously reported by D'Angelo, et al.⁷. Here we report on safety events across all cohorts.

Biomarkers. Exploratory biomarker endpoints included correlation of expansion, phenotype, and functionality of lete-cel in the blood and or tumor with response to treatment as well as correlation of biomarkers in tumor tissue and blood with response following infusion of lete-cel. The correlation of expansion with response was previously reported by D'Angelo, et al. for Cohort 1⁷. The expansion levels per cohort were summarized by Ramachandran, et al. for all cohorts⁸. Here we report on additional associations of LDR and cell dose with cell expansion, as well as associations of product attributes, cytokines and tumor gene expression with response.

T-cell expansion and phenotypic analyses

T-cell expansion analysis. Peripheral blood mononuclear cell (PBMC) samples were collected and monitored for expansion of gene-modified cells in patients at baseline (7 days prior to chemotherapy); days 4 and 7; weeks 2, 4, and 8; and months 3, 6, and 12 post-infusion. Thereafter, samples were collected every 3 months until 2 years; every 6 months until 5 years; and then every year until 15 years post-infusion. Total DNA was purified using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Presence of the WPRE or Psi transgenes (part of lentiviral vector used to transduce the T cells) was measured with custom Taqman probes by quantitative polymerase chain reaction (qPCR) on ViiA7 Real Time PCR System (Life Technologies, Waltham, MA) at Cambridge Biomedical (now part of BioAgilytix, Boston, MA). Cell kinetics or expansion was determined by quantifying the DNA copy number based on a standard curve consisting of plasmid DNA containing WPRE and Psi sequences.



T-cell-phenotypic analysis. PBMC samples were collected at baseline, 1 week; 1, 2, 6, and 12 months; then every 3 months until 2 years post-infusion; and then every 6 months until 5 years post-infusion. Immunophenotyping was performed on cryopreserved PBMC samples using flow cytometry (Caprion, Montreal, Canada; now part of CellCarta).

Detection reagents and concentrations used for T-cell phenotyping Pheno 1 panel are as follows: Live/Dead Fixable Aqua Stain Kit (ThermoFisher, Catalog#:L34957,Dilution: 1/200 Lot#2157152), CD3 (Clone: UCHT1, BD Biosciences, Catalog #: 557943, Dilution: 1/100 Lot#: 9050801), CD4 (Clone: RPA-T4, BD Biosciences,Catalog #: 562658, Dilution 1/50 Lot # 8351537), CD8 (Clone:RPA-T8, BD

Fig. 6 | Tumor remodeling post lete-cel infusion. **a** Macrophage markers *CD163*, *CD68*, and *CD84* pre-infusion ($n = 10$ biologically independent samples) and at progression ($n = 5$ biologically independent samples). **b** *CD163* expression in brown by IHC in patient (Subject ID 36) in baseline and at progression biopsy (Day 125) from the same lung lesion (representative region of tissue from an IHC run). **c, d** Average expression and heatmap of IFN downstream genes pre-infusion ($n = 10$ biologically independent samples). **e** Association between *CD163* (left) and *CD68* (right) and IFN downstream genes. Line of best fit shown in blue and gray area represents 95% confidence bands. Pre-infusion samples from seven archival screening samples (-1 year pre-infusion) and three fresh baseline samples (pre-

lymphodepletion). At progression, samples consist of five samples. Box plots depict median as horizontal line within box, with box bounds as the first and third quartiles. Dots represent individual data points. Lower whisker is the minimum value of the data within 1.5 times the interquartile range below the 25th percentile. Upper whisker is the maximum value of the data within 1.5 times the interquartile range above the 75th percentile. Heatmap show z-scores per gene. Nominal two-sided p -values obtained from linear mixed effects models (a), limma models (c), and standard test for Spearman correlation coefficient (e). IFN interferon, IHC immunohistochemistry, NR non-responder, R responder.

Biosciences, Catalog #:563821, Dilution 1/800 Lot#: 9073878), CD95 (Clone: DX2, BD Biosciences, Catalog #: 563132, Dilution: 1/100 Lot#: 9003850), CCR7 (Clone: G043H7, BioLegend, Catalog #: 353226, Dilution:1/25 Lot#: B238508), CD127 (Clone: A01D5, BioLegend, Catalog #: 351310, Dilution: 1/100 Lot#: B279332), CD45RO (Clone: UCHL1, BD Biosciences, Catalog #: 560607, Dilution: 1/100 Lot#: 0310596), CD45RA (Clone: 2H4, Beckman Coulter, Catalog #: IM2711U, Dilution: 1/25 Lot#: 200080), CD25 (Clone: M-A251, BD Biosciences, Catalog #: 557753, Dilution: 1/50 Lot#:9345728), LAG-3 (Clone: N/Av, Cedarlane, Catalog #: FAB2319F, Dilution: 2/25 Lot#: ABCB0417081), TIM-3 (Clone: 344823, Cedarlane, Catalog #: FAB2365A, Dilution: 1/25 Lot#: ABFB0417101), PD-1 (Clone: EH12.2H7, BioLegend, Catalog #: 329930, Dilution: 1/50 Lot#: B290009), and NY-ESO-1 Pentamer (HLA-A*0201, ProImmune, Dilution: 1/100 Lot#:TP/7712-21). Detection reagents and concentrations used for T-cell phenotyping Pheno 2 panel are as follows: Live/Dead Fixable Aqua Stain Kit (ThermoFisher, Catalog#:L34957, Dilution: 1/200 Lot#2157152), CD3 (Clone: OKT3, BioLegend, Catalog #: 317328, Dilution: 1/400 Lot#: B289427), CD4 (Clone: RPA-T4, BioLegend, Catalog #:300554, Dilution: 1/50 Lot #B309549), CD8 (Clone:RPA-T8, BD Biosciences, Catalog #:563821, Dilution 1/800 Lot#: 9073878), CD28 (Clone: CD28.2, BD Biosciences, Catalog #: 562976, Dilution: 1/50 Lot#:0265818), CD27 (Clone: O323, Life Technologies, Catalog #: 47-0279-42, Dilution: 1/50 Lot#: 2114191), CD103 (Clone: Ber-ACT8, BD Biosciences, Catalog #: 563883, Dilution: 1/200 Lot#:0247897), CD154/CD40L (Clone: TRAP1, BD Biosciences, Catalog #: 563589, Dilution: 2/25 Lot#:0030198), CD278/ICOS (Clone: DX29, BD Biosciences, Catalog #: 562833, Dilution: 1/50 Lot#:9317172), CD134/OX-40 (Clone: ACT35, BD Biosciences, Catalog #: 563663, Dilution: 1/100 Lot#: 0065008), CD137/4-1BB (Clone: 4B4-1, BioLegend, Catalog #: 309816, Dilution: 2/25 Lot#:B292000), CT152/CTLA-4 (Clone: BNI3, BD Biosciences, Catalog #: 562743, Dilution: 1/50, Lot#: 0030269), CD274/PD-L1 (Clone: MIH1, BD Biosciences, Catalog #: 558065, Dilution: 2/25 Lot#:9143730), and NY-ESO-1 Pentamer (HLA-A*0201, ProImmune, Dilution: 1/100 Lot#:TP/7712-21). See more details in Table S7. PBMCs were thawed (1×10^6 cells/panel) and incubated with Fc blocker (for Pheno2 only) for 10 min at room temperature, prior to being washed and subjected to pentamer staining (10 min at room temperature). PBMCs were then washed and stained with surface stainer (30 min at 4 °C), then washed again and fixed in 0.5% paraformaldehyde (30 min at 4 °C). Cells were then washed again before acquisition. Data was acquired on LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software (BD). Gating strategy is shown in Fig. S9. Hierarchical gating was used for all markers except stem-cell memory cells, which used Boolean gating (CD45RA + CCR7 + CD45RO-CD95 + CD127+).

Serum cytokine analysis

Concentration of serum cytokines was measured at baseline; day 0 pre-infusion; 1, 4, and 7 days post-infusion; and 2, 3, 4, 6, and 8 weeks post-infusion by the Meso Scale Discovery (MSD) immunoassay at Cambridge Biomedical (Boston, MA; now part of BioAgilytix). Three commercially available kits (V-PLEX Proinflammatory Panel 1; V-PLEX Cytokine Panel 1 and U-PLEX Biomarker Group 1) were used to collectively analyze the cytokine profiles of GM-CSF, IFN- γ , IL1 α , IL1 β ,

IL-1RA, IL-2, IL-2R α , IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, TNF- α , TNF- β and VEGF-A. Data was collected using the MESO QuickPlex SQ120 (MSD).

Analyses of tumor biopsies


RNA analysis. RNA analysis was performed by Histogenex (Wilrijk, Belgium; now part of CellCarta). For each sample, five 4 μ m unstained slides were used for macrodissection and subsequent RNA extraction. RNA extract was quantified (including assessment of RNA purity) using the Quant-iT RiboGreen RNA Reagent and Kit, and RNA quality was assessed using Agilent RNA Pico chip analysis.

RNA was analyzed using the NanoString nCounter[®] system, with 2 sets of NanoString assays (nCounter[®] PanCancer Immune Profiling Panel and nCounter[®] PanCancer Pathway Panel) run on the same extract. The normalization for raw nCounter counts of expressed genes is separately done for QC-passed samples in PanCancer immune and PanCancer pathway panel using the R-package NanoStringNorm (R version 4.0.3) with a set of parameters; CodeCount = 'geo.mean', Background = 'mean.2sd', SampleContent = 'housekeeping.geo.mean', round.values = TRUE, take.log = TRUE.

Detection of TCR T cells by RNA in situ hybridization. RNA in situ hybridization on biopsied tissues was performed using the RNAscope[®] 2.5 HD Duplex Reagent Kit (Advanced Cell Diagnostics, Newark, CA) comprising TCR T cell and CD3 mRNA detection assays. 5- μ m formalin-fixed, paraffin-embedded (FFPE) tissue sections were pretreated with heat and protease prior to hybridization with the target oligo probes. Pre-amplifier, amplifier, and horseradish peroxidase/alkaline phosphatase-labeled oligos were then hybridized sequentially, followed by chromogenic precipitate development.

Each sample was quality controlled for RNA integrity with an RNAscope[®] probe specific to PPIB/POLR2A RNA and for background with a probe specific to bacterial dapB RNA. The RNAscope[®] CD3 probe comprised a pool of three human CD3 antigens (CD3d, CD3e, and CD3g, Advanced Cell Diagnostics, Catalog #: 426628) mRNA, whereas the TCR probe was custom-made. Specific RNA staining signal was identified as green or red punctate dots. Samples were counterstained with hematoxylin. Representative images were digitally obtained using CaseViewer (3D Histech, Budapest, Hungary).

Protein expression by IHC. NY-ESO-1 staining was performed using the E978 clone (Sigma, Catalog #: N2038, at 1 μ g/mL) at QualTek Laboratory (Goleta, CA; now part of Discovery Life Sciences). The following markers were analyzed at Histogenex (Wilrijk, Belgium; now part of CellCarta) by IHC (all analyzed using Ventana Benchmark XT unless noted otherwise): CD4 (clone SP35, Ventana, catalog #: 790-4423, no dilution), CD8 (clone C8/144B, Dako, catalog #: M7103, 1/75 dilution), CD20 (clone L26, Ventana, catalog #: 760-2531, no dilution), CD45 (clone 2B11 + PD7/26, Agilent; catalog #: M070101, 1/100 dilution, staining on autostainer), CD163 (clone MRQ-26, Ventana, catalog #: 760-4437, no dilution), LAG-3 (clone 17B4, Novus biologicals, catalog #:97657, 1/2000 dilution), Pan Keratin (clone AE1/AE3/PCK16, Ventana, catalog #: 760-2595, no



dilution), PD-1/CD279 (clone SP269, Abcam, catalog #: GR3208557-2, 1/50 dilution), PD-L1 (clone SP142, Ventana, catalog #: M4424, 1/250 dilution), and TIM-3 (clone D5D5R, Cell Signaling Technologies, catalog #: 45208, 1/250 dilution). Representative images were digitally obtained using CaseViewer (3D Histech, Budapest, Hungary).

Statistical analysis

Populations for analysis. The intent-to-treat (ITT) population included all enrolled patients, whereas the modified ITT (mITT) population, used for safety and efficacy assessments, included patients who received lete-cel infusion. The population for biomarker analyses included patients who received lete-cel infusion with available

Fig. 7 | Decreased expression of HLA-A and antigen-presenting genes at progression. **a** Change in gene expression of *CTAG1* (NY-ESO-1) and *HLA-A* between pre-infusion ($n = 10$ biologically independent samples) and at progression ($n = 5$ biologically independent samples). **b** Average expression and heatmap of antigen presentation genes at pre-infusion ($n = 10$ biologically independent samples) and progression ($n = 5$ biologically independent samples). The following genes had background expression across all samples: *KLRC2*, *KIR3DL2*, *KIR3DL1*, *KIR2DS1*, and *KR2DL1*. **c** Persistence of lete-cel in blood of patient 32. **d** Characterization of patient 32 biopsy taken 919 days post-infusion. RNAScope results show CD3 cells in blue and lete-cel in red (left) (representative region of tissue from an IHC run). PDL1 and LAG3 staining in brown by IHC (middle and right images). Tumor samples were

primarily from lung metastases. Pre-infusion samples from seven archival screening samples (-1 year pre-infusion) and three fresh baseline samples (pre-lymphodepletion). At progression, samples consist of five samples. Box plots depict median as horizontal line within box, with box bounds as the first and third quartiles. Dots represent individual data points. Lower whisker is the minimum value of the data within 1.5 times the interquartile range below the 25th percentile. Upper whisker is the maximum value of the data within 1.5 times the interquartile range above the 75th percentile. Heatmaps show z-scores per gene. Nominal two-sided p -values obtained from linear mixed effects models (**a**, **b**). HLA human leukocyte antigen, IHC immunohistochemistry, NR non-responder, R responder.

biomarker data; sample size for each population is specified in figure legends.

Endpoint analyses. The primary endpoint for the study was pre-defined as objective response (ORR) using RECIST v1.1 based on Investigator assessment. A sensitivity analyses by Independent Review was also assessed. The ORR for each cohort of the mITT population was evaluated using 95% Clopper-Pearson confidence intervals.

Secondary efficacy endpoints included best overall response (BoR), duration of response (DoR), progression-free survival (PFS) and overall survival (OS) were evaluated using descriptive statistics and Kaplan–Meier plots as appropriate. PFS was defined as the time from T-cell infusion to the earliest documentation of disease progression or death from any cause or surgical resection or start of prohibited medication. OS was defined as the time from t-cell infusion to death due to any cause. For this analysis data from the parent study and the long-term follow-up study were included up to the data cut-off of April 23, 2021. Subjects known to be alive at this time were censored for the OS analysis.

Exploratory biomarker endpoints were evaluated as specified below. As these were exploratory endpoints, the study was not powered to evaluate these assessments. P -values are presented for descriptive purposes and are nominal (unadjusted) unless noted otherwise.

Evaluation of expansion correlates. Post-hoc relationships between cell expansion, biomarker expression, and efficacy were evaluated in a hypothesis-driven manner using Wilcoxon, logistic, linear, and median regression (R version 3.5.1), after log-transforming data when appropriate.

Flow cytometry analysis. For flow cytometry analysis, all samples with <5000 viable CD3+ cells in either the Pheno1 or Pheno2 panel were removed in downstream analysis. When the frequency for the Pentamer+ parent gate for a sample was lower than the noise level determined from the maximum value for negative control samples (healthy donors in which there should not be any Pentamer+ cells), we applied a flooring by setting the frequency of the parent gates to 0 and subsequent children gates to 'not available' for all samples. This flooring was separately done for each CD8+ Pentamer and CD4+ Pentamer+ populations. To calculate the number of transduced cells for memory phenotypes, we first calculated the percentage of CD4+ cells among Pentamer+ cells (%CD4+ Pentamer+) using the counts of CD3+ CD4+ Pentamer+ and CD3+ CD8+ Pentamer+ cells in product as % CD4+ Pentamer+ = (number of CD3+ CD4+ Pentamer+)/((number of CD3+ CD4+ Pentamer+) + (number of CD3+ CD8+ Pentamer+)). Accordingly, the percentage of CD8+ cells among Pentamer+ cells (% CD8+ Pentamer+) was inferred as 1 - %CD4+ Pentamer+. Then, the number of transduced cells of memory phenotype X for each sample was inferred as (number of CD4+ Pentamer+ X phenotype) = (% CD4+ Pentamer+) × (number of transduced cells in sample) × % CD4+ Pentamer+ X +. The number of transduced cells of CD8+ Pentamer+ memory phenotype X was done similarly. P -values in

downstream statistical analyses were based on the Wilcoxon rank sum test, whereas correlations were based on Spearman correlation coefficients.

Cytokine analysis. Cytokine analysis was based on a linear mixed effects model, log-transformed cytokine level modeled with treatment × time interactions and a random subject intercept (with otherwise independent errors). For cytokines having ≤ 1 left-censored (below lower limit of quantification) value, the R-package lme4 (version 1.1–23) was used. For cytokines having ≥ 2 left-censored values, left censoring was addressed using the R-package lme4⁵⁶ (version 1.0). In all cases Kenward & Roger⁵⁷ degrees-of-freedom were used, calculated for lme4 models using the R-package pbkrtest (version 0.4–8.6). Continuous AR1 models were also fit for cytokines having ≤ 1 left-censored value; although they often resulted in better BIC values, they did not change substantive conclusions. As lme4 does not support continuous AR-1 models, independence models were kept for all cytokines. Analyses were conducted in R version 4.0.2.

RNA analysis. For RNA analysis, both gene-level and gene-set analyses were conducted for Nanostring data, with each of the two panels fit separately. ORR comparisons were based on limma models⁵⁸ and implemented via the limma R/Bioconductor package (version 3.44.3), with log₂-expression as response and ORR as a single covariate. Pre-treatment versus At-Progression comparisons were conducted using linear mixed effects models (lme4, version 1.1–23) to address repeated measures.

PFS comparisons were based on Cox proportional hazards models with PFS as response and log₂- expression as a single covariate. To summarize differential expression across gene sets, global significance statistics were based on t -statistics from each gene within a set of interest ($\sqrt{\sum t^2}$). Corresponding p -values were obtained by permutation test (5000 permutations). Similarly, Competitive Fisher test odds ratios were based on cross-tabulation of gene set membership with nominal significance ($p < 0.05$); p -values were obtained by permutation test using Fisher Exact test p -value as objective function. Gene sets were obtained by selecting collections from KEGG (all HSA sets), GO (immune and cellular communication processes), REACTOME (all HSA sets), MsigDB (C4, C6, and Hallmarks), and a few other hand-curated sets obtained from Nanostring files or literature review^{59,60}; only gene sets with ≥ 5 overlapping non-constant genes and $\geq 50\%$ coverage of the original gene set on the respective panel were considered. Analyses were conducted in R version 4.0.2.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

For reasons of privacy protection for study participants, GSK offers access to data and materials via controlled access. Anonymized individual participant data from this study plus the annotated case report form, protocol, reporting and analysis plan, dataset specifications, raw

dataset, analysis-ready dataset, and clinical study report are available for research proposals approved by an independent review committee. Proposals should be submitted to www.clinicalstudydatarequest.com. Responses typically take within 30–45 days for the initial feasibility check. A data access agreement will be required. The data access agreement contains the terms under which GSK will provide access to researchers and institutions to GSK's clinical data. Data access recipients will be required to handle the data in accordance with data protection laws and have appropriate information security systems in place. The agreement also requires that the results of the research conducted using GSK's data must subsequently be published, either in a scientific journal or pre-print option, and that any software or models developed in the research must be released with open-source access. The RNA gene expression data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus⁶¹ and are accessible through GEO Series accession number [GSE202981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202981).

Code availability

Quantification and statistical analyses for all data types was conducted using publicly available packages in R.

References

- Rohaam, M. W., Wilgenhof, S. & Haanen, J. B. A. G. Adoptive cellular therapies: the current landscape. *Virchows Arch.* **474**, 449–461 (2019).
- Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. *N. Engl. J. Med.* **378**, 439–448 (2018).
- Chandran, S. S. & Klebanoff, C. A. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. *Immunological Rev.* **290**, 127–147 (2019).
- Zhang, J. & Wang, L. The emerging world of TCR-T cell trials against cancer: a systematic review. *Technol. cancer Res. Treat.* **18**, 1533033819831068 (2019).
- Liu, Q., Cai, W., Zhang, W. & Li, Y. Cancer immunotherapy using T-cell receptor engineered T cell. *Annals of Blood* **5** (2020).
- Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. *Nat Med.* <https://doi.org/10.1038/s41591-020-01225-1> (2021).
- D'Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. *Cancer Disco.* **8**, 944–957 (2018).
- Ramachandran, I. et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. *J. Immunother. Cancer* **7**, 276 (2019).
- Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. *Clin. Cancer Res.* **21**, 1019–1027 (2015).
- Milone, M. C. & Bhoj, V. G. The pharmacology of T cell therapies. *Mol. Ther. Methods Clin. Dev.* **8**, 210–221 (2018).
- Nielsen, T. O., Poulin, N. M. & Ladanyi, M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. *Cancer Disco.* **5**, 124–134 (2015).
- Hale, R., Sandakly, S., Shipley, J. & Walters, Z. Epigenetic targets in synovial sarcoma: a mini-review. *Front. Oncol.* <https://doi.org/10.3389/fonc.2019.01078> (2019).
- Lai, J. P., Rosenberg, A. Z., Miettinen, M. M. & Lee, C. C. NY-ESO-1 expression in sarcomas: a diagnostic marker and immunotherapy target. *Oncoimmunology* **1**, 1409–1410 (2012).
- Dallos, M., Tap, W. D. & D'Angelo, S. P. Current status of engineered T-cell therapy for synovial sarcoma. *Immunotherapy* **8**, 1073–1080 (2016).
- Pollack, S. M. et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. *Cancer* **123**, 3291–3304 (2017).
- Dancsok, A. R. et al. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. *Oncoimmunology* **9**, 1747340–1747340 (2020).
- Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. *Nature* **541**, 321–330 (2017).
- Oike, N. et al. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. *Cancer Sci.* **109**, 3043–3054 (2018).
- Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med.* **9**, 34 (2017).
- Cancer Genome Atlas Research Network Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. *Cell* **171**, 950–965.e928 (2017).
- Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARCO28): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *Lancet Oncol.* **18**, 1493–1501 (2017).
- Maki, R. G. et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. *Sarcoma* **2013**, 168145–168145 (2013).
- Hirayama, A. V. et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. *Blood* **133**, 1876–1887 (2019).
- Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 Levels. *J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol.* **35**, 1803–1813 (2017).
- Muranski, P. et al. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? *Nat. Clin. Pract. Oncol.* **3**, 668–681 (2006).
- Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. *J. Exp. Med.* **202**, 907–912 (2005).
- Ramos, C. A. et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. *J. Clin. Oncol.* **38**, 3794–3804 (2020).
- Hegde, M. et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. *Nat. Commun.* **11**, 3549 (2020).
- Wooldridge, L. et al. Tricks with tetramers: how to get the most from multimeric peptide-MHC. *Immunology* **126**, 147–164 (2009).
- Boulch, M. et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. *Sci. Immunol.* <https://doi.org/10.1126/sciimmunol.abd4344> (2021).
- D'Angelo, S. P. et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. *Hum. Pathol.* **46**, 357–365 (2015).
- Nabeshima, A. et al. Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. *Br. J. Cancer* **112**, 547–555 (2015).
- Lee, A. J. & Ashkar, A. A. The dual nature of type I and type II interferons. *Front. Immunol.* **9**, 2061 (2018).
- Di Franco, S., Turdo, A., Todaro, M. & Stassi, G. Role of type I and II interferons in colorectal cancer and melanoma. *Front. Immunol.* **8**, 878 (2017).
- Zhang, S. et al. Systemic interferon- γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial. *Cancer Immunol. Res.* **7**, 1237–1243 (2019).
- Borden, E. C. Interferons α and β in cancer: therapeutic opportunities from new insights. *Nat. Rev. Drug Discov.* **18**, 219–234 (2019).

37. Raj, S., Miller, L. D. & Triozzi, P. L. Addressing the adult soft tissue sarcoma microenvironment with intratumoral immunotherapy. *Sarcoma* **2018**, 9305294 (2018).
38. Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat. Med.* **24**, 563–571 (2018).
39. Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N. Engl. J. Med.* **380**, 1726–1737 (2019).
40. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N. Engl. J. Med.* **377**, 2531–2544 (2017).
41. Tietze, J. K. et al. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. *Eur. J. Cancer* **75**, 268–279 (2017).
42. Gide, T. N. et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. *Cancer Cell* **35**, 238–255.e236 (2019).
43. Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. *Nat. Med.* **26**, 1878–1887 (2020).
44. Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. *Blood Adv.* **4**, 4898–4911 (2020).
45. Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. *Science* **370**, 1328–1334 (2020).
46. Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who's who of T-cell differentiation: human memory T-cell subsets. *Eur. J. Immunol.* **43**, 2797–2809 (2013).
47. Berger, C. et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. *J. Clin. Invest.* **118**, 294–305 (2008).
48. Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. *Br. J. Cancer* **124**, 1759–1776 (2021).
49. Britten, C. M., Shalabi, A. & Hoos, A. Industrializing engineered autologous T cells as medicines for solid tumours. *Nat. Rev. Drug Discov.* **20**, 476–488 (2021).
50. Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. *Cancer Cell* **31**, 311–325 (2017).
51. Jerby-Arnon, L. et al. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. *Nat. Med.* **27**, 289–300 (2021).
52. Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. *Blood* **137**, 2621–2633 (2021).
53. Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. *Nat. Rev. Clin. Oncol.* **16**, 372–385 (2019).
54. Cheng, J. et al. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. *Front. Oncol.* **9**, 1237 (2019).
55. Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. *N. Engl. J. Med.* **375**, 2255–2262 (2016).
56. Vaida, F. & Liu, L. Fast implementation for normal mixed effects models with censored response. *J. Comput Graph Stat.* **18**, 797–817 (2009).
57. Kenward, M. G. & Roger, J. H. Small sample inference for fixed effects from restricted maximum likelihood. *Biometrics* **53**, 983–997 (1997).
58. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat. Appl. Genet. Mol. Biol.* **3**, Article3 (2004).
59. Chang, W. H. & Lai, A. G. Pan-cancer genomic amplifications underlie a WNT hyperactivation phenotype associated with stem cell-like features leading to poor prognosis. *Transl. Res.: J. Lab. Clin. Med.* **208**, 47–62 (2019).
60. Korkut, A. et al. A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF- β superfamily. *Cell Syst.* **7**, 422–437.e427 (2018).
61. Edgar, R., Domrachev, M. & Lash, A. E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* **30**, 207–210 (2002).

Acknowledgements

We thank the patients, their families, and site coordinators and staff for their involvement in this study. Study funded by GlaxoSmithKline (208466). We thank Aiman Shalabi, Laura Pearce, Laura Johnson, Jenna Tress, Tim Young, Julie Edwards, Joseph Harding, Shreyan Banerjee, Kishan Dhusia, Uma Saxena, Yash Gandhi, Meenakshi Srinivasan, Tom McKeivitt, and Martijn Brugman for their valuable contributions and feedback. Editorial support was provided by Frankie Wignall, PhD, of Fishawack Indicia Ltd, UK, and was funded by GlaxoSmithKline.

Author contributions

A.G. and I.E. conceptualized and designed the correlative analyses, generated and interpreted data. A.N.H. and E.A.H. also contributed to the conceptualization of cytokine analyses. St.Z., E.A.H., Sh.Z., J.K., D.C.T., and M.W. performed formal data analysis. St.Z., Y.-F.C., M.N., T.F., A.N.H., and G.D.F. interpreted results. J.G., R.N.K., S.P.D.A., D.M.A., W.A.C., M.D., G.D.D., B.A.V.T., and S.A.G. provided patient care and contributed to data interpretation. A.G., G.D.F., and I.E. supervised the study and analysis. A.G. and I.E. wrote the manuscript with edits and reviews from all authors.

Competing interests

A.G. is an employee of and holds stocks/shares in GSK and holds stocks/shares in Amgen. St.Z., E.A.H., J.K., M.N., T.F., M.W., D.C.T. and I.E. are employees of and hold stocks/shares in GSK. Y.F.C. is an employee of GSK. Sh.Z. is a former employee of and holds stocks/shares in GS.K. A.N.H. is a former employee of and holds stocks/shares in GSK and receives patents and royalties from Atara Biotherapeutics. J.G. is protocol investigator for SARC and PBTC sponsored studies. R.N.K. and D.M.A. have no disclosures. S.P.D.A. participated on advisory boards for GSK, Nektar, Adaptimmune, and Merck; reports consulting fees from EMD Serono, Amgen, Nektar, Immune design, GSK, Incyte, Merck, Adaptimmune, and Immunocore, and received support for travel expense by Adaptimmune, EMD Serono, and Nektar. WAC reports grant and honoraria received from GSK. M.D. has received consulting fees from Adaptimmune and honoraria from Deciphera. GDD reports leadership roles with Blueprint Medicines, Merrimack Pharmaceuticals (ended Oct 2019), and Translate Bio (ended Sept 2021); stocks/options/shares in Blueprint Medicines, G1 Therapeutics, Caris Life Sciences, Erasca Pharmaceuticals, RELAY Therapeutics, Bessor Pharmaceuticals, CellCarta, IKENA Oncology, Kojin Therapeutics, and IDR; paid consulting fees from Bayer, Pfizer, Novartis, Roche/Genentech, GSK, PharmaMar, Daiichi Sankyo, GSK, EMD-Serono, MEDSCAPE, Mirati, WCG/Arsenal Capital, MJ Hennessey/OncLive, C4 Therapeutics, Synlogic, McCann Health, G1 Therapeutics, Caris Life Sciences, RELAY Therapeutics, CellCarta, IKENA Oncology, Kojin Therapeutics and IDR; royalties, patents or licenses from Novartis via Dana Farber for “use patent” of imatinib in GIST; and non-financial interests in AACR Science Policy and Government Affairs Committee and Alexandria Real Estate Equities summit conference series. BAVT received consulting fees from ADRx, Ayala Pharmaceuticals, Cytokinetics Inc, and Bayer; has honoraria from Adaptimmune Ltd, GSK, Bionest Partiners, and Intellisphere LLC; has received payment for expert testimony from Hinshaw & Culbertson LLP, Rodney Law, CRICO Risk Management Foundation, and Tracey &

Fox Law Firm; has received research funding from GSK, Merck, Pfizer, and Tracoon; has received travel, accommodations, and expenses from GSK and Adaptimmune; has participated on advisory board meeting with Adaptimmune Ltd, Apexigen Inc, Boehringer Ingelheim, Daiichi Sankyo, Deciphera Pharmaceuticals Inc, Epizyme, GSK, Novartis, PTC Therapeutics, and Lilly, and is a board member for Polaris; and holds royalties or licenses for work performed with Accuronix Therapeutics. S.A.G. has received grants for study support from Novartis, Jazz Pharmaceuticals, Kite, Vertex, and Servier; has received consulting fees from Novartis, Roche, GSK, Vertex/CRISPR, CBMG, and Janssen/JnJ; has received payment for expert testimony from Irwin Mitchell and Jones Day; has patents managed according to the University of Pennsylvania patent policy; has participated on advisory boards for Novartis, Jazz Pharmaceuticals, Adaptimmune, Cellectis, Juno, Vertex, Allogene, and Cabaletta. G.D.F. is a former employee of GSK and has stock options in GSK and PACT Pharma, and holds stocks in Bluebird Bio, Agios, and BioMarin.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-022-32491-x>.

Correspondence and requests for materials should be addressed to Ioanna Eleftheriadou.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022